Ascentage Pharma (6855.HK) today announced that it will release results from the Phase I first-in-human study of APG-1387, the company’s investigational inhibitor of apoptosis protein (IAP) antagonist, in patients with chronic hepatitis B (CHB), in an oral presentation at the 73th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). Prof. Jinlin Hou, Director of the Center for Liver Diseases and the Institute of Hepatology at the Southern Medical University Affiliated Nanfang Hospital, is the principal investigator of this study.
This presentation will mark the first data readout reporting favorable safety and preliminary efficacy of an IAP antagonist for the treatment of CHB, signifying that the targeted induction of apoptosis and immune modulation in hepatitis B virus-infected cells by IAP antagonists may provide a revolutionary approach for functionally curing hepatitis B.
The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology. This year’s congress will take place both online and in-person in Washington, DC, the United States, during November 4th to 8th, 2022.
“We are thrilled to have the opportunity to present on APG-1387, our inhouse designed and developed novel IAP antagonist, to top hepatology experts and researchers from around the world, because being selected by the event signifies the recognition of Ascentage Pharma’s R&D capabilities and global innovation strategy,” said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. “At the meeting, we will announce detailed results from a Phase I study of APG-1387 in Chinese patients with CHB, and discuss the compound’s therapeutic potential for the treatment of this condition. IAP inhibitors could potentially bring a new class of drugs to the treatment of CHB, and this is why are particularly excited to share these results at the meeting.”
Title: First-in-Human Study of APG-1387, Targeting Inhibitor of Apoptosis Proteins, For the Treatment of Patients with Chronic Hepatitis B